Abstract
Major depressive disorder is a multifactorial disease, with molecular mechanisms not fully understood. A breakthrough could be reached with a panel of diagnostic biomarkers, which could be helpful to stratify patients and guide physicians to a better therapeutic choice, reducing the time between diagnostic and remission. This review brings the most recent works in proteomic biomarkers and highlights several potential proteins that could compose a panel of biomarkers to diagnostic and response to medication. These proteins are related to immune, inflammatory, and coagulatory systems and may also be linked to energy metabolism, oxidative stress, cell communication, and oligodendrogenesis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G et al (2011) Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 9:90. https://doi.org/10.1186/1741-7015-9-90
World Health Organization (2017) Depression and other common mental disorders: global health estimates. World Heal Organ. 1–24. doi: CC BY-NC-SA 3.0 IGO
Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman ATF, Penninx BWJH (2013) Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry 18:692–699. https://doi.org/10.1038/mp.2012.144
KS A-H (2012) Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 6:369–388. https://doi.org/10.2147/PPA.S29716
Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O et al (1999) Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9:83–91
Paris J (2014) The mistreatment of major depressive disorder. Can J Psychiatry 59:148–151. https://doi.org/10.1177/070674371405900306
Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358:55–68. https://doi.org/10.1056/NEJMra073096
Striegel-Moore R (2011) Developing an evidence-based classification of eating disorders: scientific findings for DSM-5, 1st edn. American Psychiatric Publishing, Washington, DC. ISBN:9780890426661
Stassen HH, Angst J, Delini-Stula A (1997) Delayed onset of action of antidepressant drugs? Survey of recent results. Eur Psychiatry 12:166–176
Fava M, Davidson KG (1996) Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179–200
Duric V, Duman RS (2013) Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell Mol Life Sci 70:39–53
Post RM (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149:999–1010
Vialou V, Feng J, Robison AJ, Nestler EJ (2013) Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharmacol Toxicol 53:59–87. https://doi.org/10.1146/annurev-pharmtox-010611-134540
Lopizzo N, Bocchio Chiavetto L, Cattane N, Plazzotta G, Tarazi FI, Pariante CM et al (2015) Gene-environment interaction in major depression: focus on experience-dependent biological systems. Front Psychiatry 6:68. https://doi.org/10.3389/fpsyt.2015.00068
López-Muñoz F, Alamo C (2009) Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 15:1563–1586
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509–522
Paul IA, Skolnick P (2003) Glutamate and depression. Ann N Y Acad Sci 1003:250–272
Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62:63–77
Schiepers OJG, Wichers MC, Maes M (2005) Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29:201–217
Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19:11–38
Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW (2008) Interleukin-1β impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging 29:1380–1393
Hayley S (2014) The neuroimmune-neuroplasticity interface and brain pathology. Front Cell Neurosci 8:419. https://doi.org/10.3389/fncel.2014.00419
Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33:88–109
Rush AJ (2007) The varied clinical presentations of major depressive disorder. J Clin Psychiatry 68(Suppl 8):4–10
Ostergaard SD, Jensen SOW, Bech P (2011) The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatr Scand 124:495–496686
Wang PS, Insel TR (2010) NIMH-funded pragmatic trials: moving on. Neuropsychopharmacology 35:2489–2490
CONVERGE consortium (2015) Sparse whole-genome sequencing identifies two loci for major depressive disorder. Nature 523:588–591
Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D et al (2011) Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol Psychiatry 16:516–532
Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160:636–645
Glahn DC, Knowles EEM, McKay DR, Sprooten E, Raventós H, Blangero J et al (2014) Arguments for the sake of endophenotypes: examining common misconceptions about the use of endophenotypes in psychiatric genetics. Am J Med Genet B Neuropsychiatr Genet 165B:122–130
Hasler G, Drevets WC, Manji HK, Charney DS (2004) Discovering endophenotypes for major depression. Neuropsychopharmacology 29:1765–1781
Goldstein BL, Klein DN (2014) A review of selected candidate endophenotypes for depression. Clin Psychol Rev 34:417–427
Lenzenweger MF (2013) Endophenotype, intermediate phenotype, biomarker: definitions, concept comparisons, clarifications. Depress Anxiety 30:185–189
Gadad BS, Jha MK, Czysz A, Furman JL, Mayes TL, Emslie MP et al (2018) Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks. J Affect Disord 233:3–14
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
Strawbridge R, Young AH, Cleare AJ (2017) Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr Dis Treat 13:1245–1262
Macaluso M, Preskorn SH (2012) How biomarkers will change psychiatry: from clinical trials to practice. Part I: introduction. J Psychiatr Pract 18:118–121
Jentsch MC, Van Buel EM, Bosker FJ, Gladkevich AV, Klein HC, Oude Voshaar RC et al (2015) Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. Biomark Med 9:277–297
Lim MD, Dickherber A, Compton CC (2011) Before you analyze a human specimen, think quality, variability, and bias. Anal Chem 83:8–13
Elliott P, Peakman TC (2008) The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol 37:234–244
Su S-Y, Hogrefe-Phi CE, Asara JM, Turck CW, Golub MS (2016) Peripheral fibroblast metabolic pathway alterations in juvenile rhesus monkeys undergoing long-term fluoxetine administration. Eur Neuropsychopharmacol 26:1110–1118
Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867
Urbas L, Brne P, Gabor B, Barut M, Strlic M, Petric TC et al (2009) Depletion of high-abundance proteins from human plasma using a combination of an affinity and pseudo-affinity column. J Chromatogr A 1216:2689–2694
Anderson NL, Leigh Anderson N, Anderson NG (2003) The human plasma proteome: history, character, and diagnostic prospects: fig 3. Mol Cell Proteomics 2:50–50
Putnam FW (2012) The plasma proteins: structure, function, and genetic control, 2nd edn. Elsevier, New York. ISBN:9780323138086
Jambunathan K, Galande AK (2014) Sample collection in clinical proteomics—proteolytic activity profile of serum and plasma. Proteomics Clin Appl 8:299–307
Martins-de-Souza D, Harris LW, Guest PC, Turck CW, Bahn S (2010) The role of proteomics in depression research. Eur Arch Psychiatry Clin Neurosci 260:499–506
Licznerski P, Duman RS (2013) Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience 251:33–50
Stelzhammer V, Haenisch F, Chan MK, Cooper JD, Steiner J, Steeb H et al (2014) Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients. Int J Neuropsychopharmacol 17:1599–1608
Lee MY, Kim EY, Kim SH, Cho K-C, Ha K, Kim KP et al (2016) Discovery of serum protein biomarkers in drug-free patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 69:60–68
Kim EY, Lee MY, Kim SH, Ha K, Kim KP, Ahn YM (2017) Diagnosis of major depressive disorder by combining multimodal information from heart rate dynamics and serum proteomics using machine-learning algorithm. Prog Neuropsychopharmacol Biol Psychiatry 76:65–71
Wang Q, Su X, Jiang X, Dong X, Fan Y, Zhang J et al (2016) iTRAQ technology-based identification of human peripheral serum proteins associated with depression. Neuroscience 330:291–325
Haines RJ, Pendleton LC, Eichler DC (2011) Argininosuccinate synthase: at the center of arginine metabolism. Int J Biochem Mol Biol 2:8–23
Wu D, Peng Y, Zhou J, Yang Y-T, Rao C-L, Bai S-J et al (2015) Identification and validation of argininosuccinate synthase as a candidate urinary biomarker for major depressive disorder. Clin Chim Acta 451:142–148
Grunze H (2011) The clinical side of bipolar disorders. Pharmacopsychiatry 44(Suppl 1):S43–S48.
Preece RL, Han SYS, Bahn S (2018) Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders. Expert Rev Proteomics 15:325–340
Stelzhammer V, Alsaif M, Chan MK, Rahmoune H, Steeb H, Guest PC et al (2015) Distinct proteomic profiles in post-mortem pituitary glands from bipolar disorder and major depressive disorder patients. J Psychiatr Res 60:40–48
Fleming CE, Nunes AF, Sousa MM (2009) Transthyretin: more than meets the eye. Prog Neurobiol 89:266–276
Frye MA, Nassan M, Jenkins GD, Kung S, Veldic M, Palmer BA et al (2015) Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. Transl Psychiatry 5:e689. https://doi.org/10.1038/tp.2015.185
Ren J, Zhao G, Sun X, Liu H, Jiang P, Chen J et al (2017) Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis. Psychoneuroendocrinology 86:17–24
Yang Y, Chen J, Liu C, Fang L, Liu Z, Guo J et al (2016) The extrinsic coagulation pathway: a biomarker for suicidal behavior in major depressive disorder. Sci Rep 6:32882. https://doi.org/10.1038/srep32882
Aziz R, Steffens DC (2013) What are the causes of late-life depression? Psychiatr Clin North Am 36:497–516
Diniz BS, Lin C-W, Sibille E, Tseng G, Lotrich F, Aizenstein HJ et al (2016) Circulating biosignatures of late-life depression (LLD): towards a comprehensive, data-driven approach to understanding LLD pathophysiology. J Psychiatr Res 82:1–7
Diniz BS, Sibille E, Ding Y, Tseng G, Aizenstein HJ, Lotrich F et al (2015) Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Mol Psychiatry 20:594–601
Diniz BS, Reynolds CF 3rd, Sibille E, Lin C-W, Tseng G, Lotrich F et al (2017) Enhanced molecular aging in late-life depression: the senescent-associated secretory phenotype. Am J Geriatr Psychiatry 25:64–72
Bot M, Chan MK, Jansen R, Lamers F, Vogelzangs N, Steiner J et al (2015) Serum proteomic profiling of major depressive disorder. Transl Psychiatry 5:e599. https://doi.org/10.1038/tp.2015.88
Lee J, Joo E-J, Lim H-J, Park J-M, Lee KY, Park A et al (2015) Proteomic analysis of serum from patients with major depressive disorder to compare their depressive and remission statuses. Psychiatry Investig 12:249–259
Martins-de-Souza D, Maccarrone G, Ising M, Kloiber S, Lucae S, Holsboer F et al (2014) Plasma fibrinogen: now also an antidepressant response marker? Transl Psychiatry 4:e352. https://doi.org/10.1038/tp.2013.129
Gadad BS, Jha MK, Grannemann BD, Mayes TL, Trivedi MH (2017) Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: findings from the CO-MED trial. J Psychiatr Res 94:1–6
Turck CW, Guest PC, Maccarrone G, Ising M, Kloiber S, Lucae S et al (2017) Proteomic differences in blood plasma associated with antidepressant treatment response. Front Mol Neurosci 10:272. https://doi.org/10.3389/fnmol.2017.00272
Martins-de-Souza D, Maccarrone G, Ising M, Kloiber S, Lucae S, Holsboer F et al (2014) Blood mononuclear cell proteome suggests integrin and Ras signaling as critical pathways for antidepressant treatment response. Biol Psychiatry 76:e15–e17. https://doi.org/10.1016/j.biopsych.2014.01.022
Park DI, Štambuk J, Razdorov G, Pučić-Baković M, Martins-de-Souza D, Lauc G et al (2018) Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder symptom severity and the antidepressant response. Sci Rep 8:179. https://doi.org/10.1038/s41598-017-17500-0
Chen C, Hu Y, Dong X-Z, Zhou X-J, Mu L-H, Liu P (2018) Proteomic analysis of the antidepressant effects of Shen-Zhi-Ling in depressed patients: identification of proteins associated with platelet activation and lipid metabolism. Cell Mol Neurobiol 38:1123–1135
Pisoni A, Strawbridge R, Hodsoll J, Powell TR, Breen G, Hatch S et al (2018) Growth factor proteins and treatment-resistant depression: a place on the path to precision. Front Psychiatry 9:386. https://doi.org/10.3389/fpsyt.2018.00386
Ruland T, Chan MK, Stocki P, Grosse L, Rothermundt M, Cooper JD et al (2016) Molecular serum signature of treatment resistant depression. Psychopharmacology 233:3051–3059
Stelzhammer V, Guest PC, Rothermundt M, Sondermann C, Michael N, Schwarz E et al (2013) Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. Eur Neuropsychopharmacol 23:1199–1207
Zhao H, Du H, Liu M, Gao S, Li N, Chao Y et al (2018) Integrative proteomics-metabolomics strategy for pathological mechanism of vascular depression mouse model. J Proteome Res 17:656–669
Mallei A, Failler M, Corna S, Racagni G, Mathé AA, Popoli M (2014) Synaptoproteomic analysis of a rat gene-environment model of depression reveals involvement of energy metabolism and cellular remodeling pathways. Int J Neuropsychopharmacol 18. https://doi.org/10.1093/ijnp/pyu067
Wesseling H, Rahmoune H, Tricklebank M, Guest PC, Bahn S (2014) A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain. J Proteome Res 14:411–421
Ge L, Zhu M-M, Yang J-Y, Wang F, Zhang R, Zhang J-H et al (2015) Differential proteomic analysis of the anti-depressive effects of oleamide in a rat chronic mild stress model of depression. Pharmacol Biochem Behav 131:77–86
Palmfeldt J, Henningsen K, Eriksen SA, Müller HK, Wiborg O (2016) Protein biomarkers of susceptibility and resilience to stress in a rat model of depression. Mol Cell Neurosci 74:87–95
Stelzhammer V, Ozcan S, Gottschalk MG, Steeb H, Hodes GE, Guest PC et al (2015) Central and peripheral changes underlying susceptibility and resistance to social defeat stress—a proteomic profiling study. Diagnostics in Neuropsychiatry 1:1–7. https://doi.org/10.1016/j.dineu.2015.08.001
Gottschalk MG, Wesseling H, Guest PC, Bahn S (2014) Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism. Int J Neuropsychopharmacol 18. https://doi.org/10.1093/ijnp/pyu019
Goodwin GM (2015) The overlap between anxiety, depression, and obsessive-compulsive disorder. Dialogues Clin Neurosci 17:249–260
Acknowledgments
The authors thank FAPESP (Sao Paulo Research Foundation, grants 2013/08711-3, 2017/18242-1 2017/25588-1 and 2018/03422-7) and Serrapilheira Institute (grant number Serra-1709-16349) for funding. We also thank CAPES (Coordination for the Improvement of Higher Education Personnel) for the scholarship 88887.179832/2018-00. The authors thank Prof. Brett Vern Carlson (Technological Institute of Aeronautics (ITA)) for assistance with the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Silva-Costa, L.C., Carlson, P.T., Guest, P.C., de Almeida, V., Martins-de-Souza, D. (2019). Proteomic Markers for Depression. In: Guest, P. (eds) Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders. Advances in Experimental Medicine and Biology(), vol 1118. Springer, Cham. https://doi.org/10.1007/978-3-030-05542-4_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-05542-4_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-05541-7
Online ISBN: 978-3-030-05542-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)